How does USP 797 / 800 compliance compare to FDA cGMP for insurance underwriting?

USP 797 ("Pharmaceutical Compounding — Sterile Preparations") is a United States Pharmacopeia standard for the sterile compounding environment, training, and procedures. It is enforced by state boards of pharmacy as the baseline quality standard for 503A compounding pharmacies. USP 800 ("Hazardous Drugs — Handling in Healthcare Settings") adds requirements for handling hazardous drugs (chemotherapy agents, hormones, certain antivirals, etc.).

FDA cGMP ("current Good Manufacturing Practice," 21 CFR Parts 210 and 211) is the federal standard for drug manufacturing. It is the binding quality framework for 503B outsourcing facilities, drug substance manufacturers, drug product manufacturers, and any contract manufacturer making finished drug products. cGMP is enforced by FDA inspections (Form 483 observations, warning letters, consent decrees).

cGMP covers a broader scope (manufacturing facilities, equipment qualification, process validation, batch records, quality control testing, change control, stability programs, vendor qualification) and operates on a continuous compliance basis. USP 797 focuses on the sterile compounding environment and procedures and is enforced periodically by state board inspections.

The practical implication: a facility that satisfies USP 797 may not satisfy cGMP. Transitioning from a 503A operating model to a 503B operating model requires building out cGMP-aligned quality systems (validation, batch records, change control, stability) that USP 797 does not require.

For 503A operators, carriers underwrite to USP 797 / 800 compliance as the floor. Compliance documentation (current state board inspection, environmental monitoring records, training records, sterility test results) is typically required at submission and renewal. Non-compliance can result in coverage being unavailable or written at materially higher premium.

For 503B operators, carriers underwrite to FDA cGMP compliance. FDA inspection history (Form 483 observations, warning letters, consent decree status) is the critical underwriting input. Recent observations or warning letters can result in coverage being unavailable rather than just expensive — the dedicated life-sciences markets will sometimes decline a risk with an open warning letter regardless of premium offered.

The premium differential is meaningful. A 503A in good standing at $5M revenue might pay $15,000-$25,000 annually for the core program. A comparably-sized 503B in good standing at $5M revenue might pay $75,000-$150,000 annually for a program that satisfies hospital purchase contract requirements.

503A renewal documentation typically includes (1) current state board of pharmacy inspection report, (2) USP 797 / 800 compliance attestation, (3) environmental monitoring records, (4) pharmacist license documentation, and (5) any reportable adverse events.

503B renewal documentation typically includes (1) current FDA registration confirmation, (2) most recent FDA Form 483 observations and closeout documentation, (3) any warning letters and current status, (4) cGMP quality system documentation summary, (5) batch record sampling, and (6) inspection history for the prior three years.

The renewal documentation burden is materially higher for 503B than 503A. Operators that maintain documentation discipline throughout the year find renewal smoother than operators who scramble to assemble documentation at submission time.